[Event Report] AMR Alliance Japan: Media Briefing (July 26, 2019)
date : 8/6/2019
Tags: AMR
![[Event Report] AMR Alliance Japan: Media Briefing (July 26, 2019)](https://hgpi.org/en/wp-content/uploads/sites/2/IMG_0038-1.jpg)
AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) released “AMR Alliance Japan Policy Recommendations: The Japanese Government’s Role in Promoting AMR Countermeasures” on July 11, 2019. These recommendations are the result of intensive discussion among a wide-range of infectious disease experts, and lay out a path for the Japanese Government to assume greater leadership in the fight against antimicrobial resistance (AMR).
This media briefing was held to disseminate these policy recommendations and share information on AMR-related issues with the media.
The meeting participants discussed the critical status of current AMR-related problems, the National Action Plan on AMR, guidelines for the appropriate use of antimicrobial agents, functions of infection control teams/human resources at health facilities, the promotion of public awareness on AMR, and other issues.
Organizer: AMR Alliance Japan (Secretariat: Health and Global Policy Institute)
Program: (titles omitted)
Opening (Explanatory Introduction)
Chair
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Presentation 1
Yoshiaki Gu (Chief, Information and Education Division, AMR Clinical Reference Center, National Center for Global Health and Medicine)
Presentation 2
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Q&A session
Participants (alphabetical order by last name/ titles omitted)
Kyoko Ama (Representative, Ippan Shadan Hojin Shiro Shoni Iryo Mamoro Kodomo-tachi no Kai)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Shinya Nagase (Director, Diagnostic Systems, BD Life Sciences, Nippon Becton Dickinson Company, Ltd.)
Kazunobu Ouchi (President, Japanese Society for Pediatric Infectious Diseases / Professor, School of medicine, Kawasaki Medical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control / Professor, Department of Infectious Disease and Infection Control, The Jikei University School of Medicine)
Top Research & Recommendations Posts
- [Policy Recommendation] Preparing for “Disaster-Level Heat” in the 2025 Basic Policy on Economic and Fiscal Management and Reform (June 9, 2025)
- [Event Report] Round Table Discussion “Understanding Menopausal Women’s Health as a Social Issue” (November 19, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Policy Recommendation] Integrating “Planetary Health” as a Growth Strategy — Proposal for the Grand Design and Action Plan for a New Form of Capitalism (2025 Revised Edition) (June 9, 2025)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Research Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Final Version) (November 14, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
- [Policy Recommendations] HGPI Joint Input to the Zero Draft Political Declaration on NCDs and Mental Health (May 23, 2025)
Featured Posts
-
2025-07-04
[Registration Open] (Webinar) The 136th HGPI Seminar “Where We Are Now and Where We Are Going Regarding PPI in Mental Health Research: Learning from the TOGETHER Project in the Form of Co-Creation” (July 28, 2025)
-
2025-07-04
[Recommendations] HGPI Expert Policy Advocacy Platform “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan” (May 7, 2025)
-
2025-07-08
[Registration Open] Planetary Health Academy (Starts August 2025)
-
2025-07-14
[Policy Recommendation] Ensuring Equitable Access to Cancer Gene Panel Testing and Key Considerations for Applying the Mixed Medical Services Program (April 28, 2025)
-
2025-07-16
[Event Report] 1st Chair’s Dialogue “Introduction to Public-Private Partnerships – Global Case Studies in the Healthcare Sector” (May 9, 2025)